Diagnosis and treatment of prostate cancers in renal-transplant recipients.
BACKGROUND
There is no consensus regarding prostate cancer in renal-transplant recipients (RTR). A questionnaire evaluating prostate cancer screening after transplantation and assessing the number, diagnostic modalities, treatment, and outcome of prostate cancer cases was mailed to 22 French renal-transplant centers.


RESULTS
Among 1,680 RTR in 1998, 11 (0.65%) cases of prostate cancer were diagnosed, and among the 2,338 recipients followed up, 28 (1%) cases of prostate cancer have been diagnosed and treated. Median ages at diagnosis and at transplantation were 63 and 58, respectively. Clinical stages were T1 50% and T2 25%. Eighteen patients had a Gleason score under 7. At 18 months of mean follow-up, 2 men had died from prostate cancer, and in the curative treatment group, 16 of 17 men were alive with no evidence of disease.


CONCLUSIONS
The incidence of prostate cancer in RTR appeared to be higher than expected. Prostate specific antigen (PSA) testing should be performed routinely each year in renal transplantation centers.
Cormier
Luc
L
Renal Transplantation Committee of the French Urological Association, Paris, France.
Lechevallier
Eric
E
Barrou
Benoit
B
Benoit
Gérard
G
Bensadoun
Henri
H
Boudjema
Karim
K
Descottes
Jean-Luc
JL
Doré
Bertrand
B
Guy
Laurent
L
Malavaud
Bernard
B
Martin
Xavier
X
Patard
Jean Jacques
JJ
Petit
Jacques
J
Salomon
Laurent
L
D000328:Adult; D000367:Age Factors; D000368:Aged; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000209:etiology